A MULTI-CRITERIA DECISION FRAMEWORK FOR DATA-DRIVEN PHARMACEUTICAL LICENSING

ABSTRACT

The biopharmaceutical industry increasingly relies on external innovation to sustain pipeline growth, placing heightened importance on effective prioritization of licensing and partnering opportunities. Business development and licensing teams are required to evaluate heterogeneous external assets across therapeutic areas, modalities, and stages of development, often under conditions of uncertainty and incomplete information. However, external asset prioritization is frequently driven by qualitative judgment and informal consensus, which can limit transparency, consistency, and strategic alignment.

This article presents a structured, data-driven multi-criteria decision analysis framework designed to support prioritization of external innovation assets in pharmaceutical licensing. The framework integrates commonly assessed evaluation dimensions, scientific and translational differentiation, clinical readiness, intellectual property and freedom-to-operate positioning, regulatory and development risk, competitive landscape, and commercial and strategic fit, into a hierarchical scoring model.

The framework is demonstrated using simulated and anonymized asset profiles reflecting realistic CNS, oncology, and virology development scenarios. Results show that the model effectively differentiates assets with balanced risk-value profiles from those with strong individual attributes but material downstream constraints. Overall, this work contributes a transparent and adaptable decision-support methodology for external innovation prioritization in pharmaceutical business development and licensing.

АННОТАЦИЯ

Биофармацевтическая отрасль всё активнее использует внешние источники инноваций для обеспечения устойчивого роста портфеля разработок, что повышает значимость эффективной приоритизации лицензионных и партнёрских проектов. Команды по бизнес-девелопменту и лицензированию вынуждены оценивать разнородные внешние активы в различных терапевтических областях и на разных стадиях разработки, зачастую в условиях неопределённости и ограниченности данных. При этом принятие решений нередко основывается преимущественно на экспертных оценках и неформальных процедурах согласования, что снижает прозрачность и воспроизводимость выбора.

В работе представлена структурированная многокритериальная модель поддержки принятия решений, предназначенная для приоритизации внешних инновационных активов в фармацевтическом лицензировании. Модель объединяет ключевые параметры оценки - научную и трансляционную значимость, клиническую готовность, защиту интеллектуальной собственности и свободу коммерциализации, регуляторные и разработочные риски, конкурентную среду, а также коммерческое и стратегическое соответствие - в единую иерархическую систему балльной оценки.

Применение модели продемонстрировано на симулированных профилях активов, отражающих реалистичные сценарии разработки в областях неврологии, онкологии и вирусологии. Полученные результаты показывают, что предложенный подход позволяет чётко различать проекты со сбалансированным соотношением риска и потенциала ценности и проекты, обладающие отдельными сильными сторонами, но ограниченные существенными факторами риска. Представленная методология формирует прозрачный и адаптируемый инструмент поддержки принятия решений в сфере фармацевтического бизнес-девелопмента и лицензирования.

Keywords: external innovation; pharmaceutical licensing; multi-criteria decision analysis; asset prioritization; portfolio decision-making; biopharma strategy; drug development.

Ключевые слова: внешние инновации, фармацевтическое лицензирование, многокритериальный анализ принятия решений, приоритизация активов, принятие портфельных решений, стратегия биофармацевтической компании, разработка лекарственных средств.

INTRODUCTION

The biopharmaceutical industry has increasingly shifted toward external innovation as a central driver of pipeline growth. Licensing, acquisitions, and strategic partnerships now account for a substantial share of clinical-stage and commercial assets across major pharmaceutical companies, reflecting persistent challenges in internal R&D productivity and rising development complexity [1,2]. As a result, business development and licensing (BD&L) has evolved into a core strategic function directly influencing portfolio performance and long-term value creation.

At the same time, the decision environment for BD&L organizations has become more complex. Expansion of therapeutic modalities, advances in molecular biology, and increasing specialization across disease areas have led to a growing number of heterogeneous external opportunities, often supported by early or incomplete evidence. BD&L teams must integrate assessments of scientific differentiation, intellectual property protection, regulatory feasibility, competitive positioning, and commercial potential under substantial uncertainty and time pressure. In practice, such decisions frequently rely on qualitative screening and expert judgment, which can introduce inconsistency and limited transparency in evaluation processes [3].

Empirical analyses of pharmaceutical R&D performance suggest that suboptimal prioritization, rather than lack of innovation, contributes significantly to portfolio inefficiencies. Downstream factors such as IP exclusivity, regulatory risk, and competitive dynamics often exert disproportionate influence on ultimate asset value, yet may be underweighted during early evaluation stages [1,4]. These challenges have increased interest in structured decision-support methodologies capable of integrating diverse criteria and making trade-offs explicit.

Multi-criteria decision analysis (MCDA) has been widely applied in healthcare and regulatory decision-making to improve transparency, consistency, and stakeholder alignment when evaluating heterogeneous alternatives [5]. However, most published applications focus on internal R&D selection or regulatory benefit-risk assessment, with limited attention to the specific decision context of external innovation and pharmaceutical licensing.

This article presents a structured, data-driven MCDA framework tailored to external innovation prioritization in pharmaceutical BD&L. By formalizing how scientific, IP, regulatory, competitive, and commercial dimensions are integrated into composite prioritization outputs, the proposed framework aims to support more consistent and strategy-aligned licensing decisions in an increasingly complex innovation landscape.

MATERIALS AND METHODS

This study describes the development and demonstration of a structured MCDA framework designed to support prioritization of external innovation assets in pharmaceutical BD&L. The objective was to develop a transparent and adaptable decision model capable of integrating heterogeneous evaluation criteria commonly used in licensing assessments, rather than to analyze outcomes from historical transactions. All analyses were conducted using simulated and anonymized asset profiles constructed to reflect realistic industry scenarios without reliance on confidential or proprietary data.

The MCDA framework was implemented as a modular, hierarchical scoring system translating diverse evaluation inputs into a single composite prioritization score. The architecture comprises three analytical layers: indicator-level scoring, domain-level aggregation, and weighted composite scoring. This structure enables consistent comparison of assets across therapeutic areas, modalities, and development stages, while allowing domain weights to be adjusted to reflect alternative strategic objectives.

Six evaluation domains were defined based on established BD&L decision practices: scientific and translational differentiation, clinical readiness, intellectual property and freedom-to-operate (IP/FTO) positioning, regulatory and development risk, competitive landscape, and commercial and strategic fit. Each domain comprises multiple indicators representing attributes routinely assessed during external innovation evaluations.

Quantitative indicators, such as development stage, remaining patent life, and number of competing programs, were normalized to a standardized scale prior to scoring. Qualitative indicators, including mechanism-of-action differentiation, translational relevance, regulatory complexity, and portfolio alignment, were assessed using predefined expert scoring rubrics to promote internal consistency and reduce inter-reviewer variability.

Table 1.

Representative indicators and scoring logic

All indicators were scored on a uniform numerical scale ranging from 0 to 5, where higher values represent more favorable characteristics. Within each domain, indicator scores were aggregated into a single domain score using weighted summation, with indicator weights fixed across assets to ensure comparability.

Table 2.

 Domain structure and illustrative indicator weights.

Domain scores were combined into a composite prioritization score through weighted summation, with domain weights normalized to sum to one. Baseline weights represented a balanced strategic perspective, while alternative weight configurations were used to model late-stage revenue focus, platform-driven innovation, and risk-averse portfolio strategies.

Table 3.

Example domain weight configurations

Sensitivity analyses were conducted to assess robustness of asset prioritization under varying weighting assumptions. All calculations were implemented in Microsoft Excel.

RESULTS

Application of the proposed MCDA framework to simulated external innovation asset profiles generated differentiated composite prioritization scores and interpretable rank ordering across CNS, oncology, and virology development scenarios. The framework enabled systematic comparison of heterogeneous assets by integrating scientific, intellectual property, regulatory, competitive, and commercial dimensions into a single quantitative output.

Under baseline weighting assumptions, assets exhibiting balanced performance across multiple evaluation domains consistently achieved higher composite scores than assets with strong performance in isolated dimensions. Table 4 presents composite scores, rankings, and priority tier assignments for representative simulated assets.

Table 4.

Composite prioritization results under baseline weighting

High-priority assets were characterized by favorable IP/FTO positioning and lower competitive density in addition to scientific differentiation. In contrast, assets with strong mechanistic rationale but constrained downstream profiles were deprioritized, illustrating the framework’s ability to surface risk-value trade-offs that are often obscured in qualitative screening.

Alternative strategic weighting scenarios were applied to evaluate prioritization robustness under different organizational emphases. Table 5 reports composite scores and rankings under baseline, late-stage revenue-focused, and platform innovation-focused weighting schemes.

Table 5.

Rank changes under alternative strategic weighting scenarios

Scenario-based weighting produced modest shifts in composite scores while preserving rank order, indicating that prioritization of top-tier and mid-tier assets was robust across plausible strategic emphases. This result highlights the ability of the framework to identify opportunities with durable value across multiple strategic contexts rather than being overly sensitive to weighting assumptions.

DISCUSSION

This study proposes a structured MCDA framework to support prioritization of external innovation assets in pharmaceutical business development and licensing. The results demonstrate that formalizing how scientific differentiation, intellectual property positioning, regulatory feasibility, competitive landscape, and commercial fit are integrated into a composite score enhances transparency and consistency in external asset evaluation. In an environment characterized by persistent R&D productivity challenges, improving decision quality has become central to portfolio performance and value realization rather than simply increasing scientific throughput [1,6].

Empirical analyses of pharmaceutical R&D have repeatedly shown that downstream determinants, including development risk, competitive positioning, and portfolio governance, play a critical role in ultimate asset value [4,6]. The declining efficiency of pharmaceutical R&D has been attributed not only to scientific uncertainty but also to decision and portfolio management practices [6]. By explicitly incorporating IP strength, regulatory complexity, and competitive density alongside scientific merit, the proposed framework aligns with the view that risk-adjusted value, rather than isolated novelty, should guide strategic asset prioritization.

The scenario-based weighting analyses further illustrate the strategic dependence of licensing decisions. Portfolio literature suggests that optimal project selection is contingent upon organizational objectives, capital constraints, and risk tolerance [4]. Structured frameworks that make these trade-offs explicit may reduce reliance on implicit assumptions and improve cross-functional alignment. Such transparency is particularly relevant in alliance-driven innovation models, where governance and interface management strongly influence outcomes.

The framework also addresses cognitive and organizational sources of decision variability. Behavioral decision research has demonstrated that expert judgment alone is susceptible to inconsistency and bias, particularly in high-uncertainty contexts [3]. MCDA methodologies have been widely adopted in healthcare decision-making precisely because they formalize trade-offs and improve traceability of complex evaluations [5]. Applying similar structured approaches to BD&L contexts represents a logical extension of these principles.

Several limitations warrant consideration. The framework was demonstrated using simulated asset profiles and therefore does not provide retrospective validation against historical deal outcomes. However, MCDA approaches are primarily designed to structure and clarify decision processes rather than predict precise success probabilities [5]. Future research may incorporate probabilistic success modeling, real-world licensing datasets, or integration with financial portfolio optimization methods.

As external sourcing continues to contribute substantially to pharmaceutical pipelines, structured and transparent prioritization mechanisms may become increasingly important organizational capabilities. Embedding explicit, multi-dimensional evaluation criteria into BD&L workflows has the potential to enhance consistency, strategic alignment, and governance quality in innovation-driven environments.

References:

1. Pammolli, F., Magazzini, L. & Riccaboni, M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10, 428–438 (2011). https://doi.org/10.1038/nrd3405
2. Schuhmacher A, Gassmann O, Bieniok D, Hinder M, Hartl D. Open innovation: A paradigm shift in pharma R&D? Drug Discovery Today. 2022 Sep 1;27(9):2395-405. https://doi.org/10.1016/j.drudis.2022.05.018
3. Kahneman, D., Sibony, O., & Sunstein, C. R. (2021). Noise: A Flaw in Human Judgment.
4. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010 Mar;9(3):203-14. doi: 10.1038/nrd3078. Epub 2010 Feb 19. PMID: 20168317.
5. Marsh K, IJzerman M, Thokala P, Baltussen R, Boysen M, Kaló Z, Lönngren T, Mussen F, Peacock S, Watkins J, Devlin N; ISPOR Task Force. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016 Mar-Apr;19(2):125-37. doi: 10.1016/j.jval.2015.12.016. Epub 2016 Mar 7. PMID: 27021745.
6. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012 Mar 1;11(3):191-200. doi: 10.1038/nrd3681. PMID: 22378269.